![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.50 | 2.52% | 61.00 | 57.00 | 65.00 | 61.00 | 59.50 | 59.50 | 12,246 | 14:00:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investment Advice | 149k | -7.14M | -0.1082 | -5.64 | 39.26M |
RNS Number:1287U Celsis International PLC 15 November 2000 CELSIS INTERNATIONAL PLC Appoints New Chief Executive Celsis International plc is today pleased to announce the appointment of Jay LeCoque as full-time Chief Executive Officer. Mr. LeCoque joins Celsis from OurHouse.com, the top rated internet site focused on the "home", consistently featured as one of the world's top 20 most visited internet shopping sites by MediaMetrix. Mr. LeCoque originally joined Celsis in April 1995 as Director of Global Business Development for the personal care industries. He was then appointed head of Sales and Marketing in the Americas, before taking on the role of General Manager of the Americas and helping Celsis to secure its first year of profitability. Previously Mr. LeCoque worked for Valois, a global supplier to the pharmaceutical and personal care industries, and Baxter International Inc. in a variety of sales and marketing roles. Mr. LeCoque holds a MBA from Northwestern University. Jack Rowell, the acting CEO for the last two years, will resume his role as Non-Executive Chairman of the Board. Mr. LeCoque was appointed to the Board on the 15th November 2000, and will now take the lead of the recently strengthened executive team, consisting of Christian Madrolle (Group Finance Director) and Peter Grant (Director of Technology and Business Development). Dr. Chris Evans resumes his original role as a Non-Executive Director. Jack Rowell, Non-Executive Chairman of Celsis International plc, commented: "I am pleased to announce the appointment of Jay LeCoque, and to welcome him back to Celsis as Chief Executive Officer. Jay joins us at an exciting period in the development of the Company. The management team have worked hard to establish Celsis as an innovative and profitable company producing sustainable revenue growth, having turned a loss of #4.1m into a profit of #3.0m within three years. The Board has immense confidence in Jay's experience, and his ability to continue the profitable growth of Celsis - leading the management team into new markets whilst driving development and innovation." Dr. Chris Evans, Non-Executive Director of Celsis International plc, commented: "With an excellent management team now in place, I feel that Celsis is ideally positioned for growth. Jay LeCoque is exactly the sort of person needed to drive the development of business, and with the experienced guidance of Jack Rowell, I believe that investors can be confident in the team's ability to create shareholder value. I would also like to take this opportunity to thank Jack for working beyond the call of duty in fulfilling his role as acting CEO for the last two years." Enquiries Celsis International plc Dr Peter Grant, Technology and Business Development Director +44 (0) 1223 426 008 Jenny Parsons, Corporate Communications +44 (0) 1223 426 008 Brunswick Group Melissa Miller/Juliet Marshall +44 (0) 20 7404 5959 Notes to Editors Celsis International plc Celsis International plc specialises in the development and supply of rapid diagnostic and monitoring systems to detect and measure microbial contamination. It has successfully developed tests for use in the food, beverage, pharmaceutical, cosmetic and toiletries industries. These tests are based upon the technology of ATP Bioluminescence; such tests detect the presence of microbial contamination by monitoring light emitted when adenosine triphosphate ("ATP"), a naturally occurring substance present in all living organisms, is brought into contact with luciferase, an enzyme produced by fireflies.
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions